{
    "clinical_study": {
        "@rank": "79076", 
        "acronym": "GUARDIX-FL", 
        "arm_group": [
            {
                "arm_group_label": "GUARDIX-FL", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day)."
            }, 
            {
                "arm_group_label": "Interceed", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day)."
            }
        ], 
        "brief_summary": {
            "textblock": "-  Indication: Benign tumors of ovary(mature teratoma, mucinous cystadenoma, serous\n           cystadenoma)\n\n        -  Intervention: Device ( Test group : Guardix-FL, Control group :  Interceed)\n\n        -  Primary Outcome Measure : Anti-adhesion Rate\n\n        -  Assessment : Operative Day(Visit 2), Post-Operative Day+7days(Vist 3), Post-Operative\n           Day+4weeks(Visit4), Post-Operative Day+5weeks(Visit 5)"
        }, 
        "brief_title": "Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Genital Diseases, Female", 
        "condition_browse": {
            "mesh_term": "Genital Diseases, Female"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The patients who sign the written informed consent\n\n          2. Women aged between 18 and 44\n\n          3. The patients who are able to participate in clinical trial during the period of study\n\n          4. The patients without abnormal figures at the screening laboratory examination\n\n          5. The patients expecting ovarian cystectomy for benign ovarian tumor(mature cystic\n             teratoma, Mucinous cystadenoma, serous cystadenoma)\n\n        Exclusion Criteria:\n\n          1. The patients who took treatments with medical products which might be barrier to\n             evaluate the effectiveness\n\n          2. The patients who took medicine like other anti-adhesion, absorbable hemostat and dose\n             of steroid, immunosuppressants\n\n          3. The patients with severe drug allergy\n\n          4. The patients with infectious disease on abdominal or pelvic cavity\n\n          5. The patients who previously participated in another clinical trials within the past\n             30 days\n\n          6. The patients considered inappropriate for the study\n\n          7. The pregnant\n\n          8. The patients with severe renal disease\n\n          9. The patients with severe systemic diseases"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "44 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097446", 
            "org_study_id": "Genewel1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "GUARDIX-FL", 
                "intervention_name": "Guardix-FL", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Interceed", 
                "intervention_name": "Interceed", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "cystectomy", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "lovejunjung@hanmail.net", 
                "last_name": "Hae Jeong Kim, Bachelor's", 
                "phone": "82-10-2987-0960"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "133-792"
                }, 
                "name": "Hanyang University Seoul Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study", 
        "overall_contact": {
            "email": "junho1012@idongsung.com", 
            "last_name": "Jun Ho Kim, Master", 
            "phone": "82-10-6455-3455"
        }, 
        "overall_contact_backup": {
            "email": "yzz3675@idongsung.com", 
            "last_name": "Dan Bee Youn, Bachelor's", 
            "phone": "82-10-5061-3675"
        }, 
        "overall_official": [
            {
                "affiliation": "Hanyang University Seoul Hospital", 
                "last_name": "Joong Sub Choi, Ph.D", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Severance Hospital", 
                "last_name": "Seong Hun Kim, Ph.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adhesion yes or no", 
            "measure": "Anti-Adhesion Rate", 
            "safety_issue": "No", 
            "time_frame": "Post-Operative Day+4weeks(Second - look)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097446"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Length of Adhesion x Grade of Adhesion", 
            "measure": "Score", 
            "safety_issue": "No", 
            "time_frame": "Post-Operative Day+4weeks(Second-look)"
        }, 
        "source": "Genewel Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genewel Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}